MiNK Therapeutics (NASDAQ:INKT) Releases Earnings Results, Misses Expectations By $0.02 EPS

MiNK Therapeutics (NASDAQ:INKT) posted its quarterly earnings data on Thursday. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.02), Zacks reports.

Here are the key takeaways from MiNK Therapeutics’ conference call:

• MiNK advanced agenT-797 into a randomized Phase II ARDS study, with enrollment continuing in Ukraine and U.S. sites expected to begin enrolling in September. The company expects preliminary randomized data in the first half of 2027 and is preparing to discuss a potential seamless Phase III design with the FDA.
• Initial observations from two treated patients showed survival without fever at day 28, improved oxygenation, ARDS resolution, spontaneous breathing, vasopressor liberation, infection control, and no major treatment-related serious adverse events. However, management emphasized that the data are early, non-comparative, and based on a small run-in cohort.
• MiNK launched its first international paid named-patient access program in Brazil, generating physician-directed access and payments while building cross-border logistics and regulatory infrastructure. The company said additional patients were treated after quarter-end and that further financial details are expected with its third-quarter update.
• MiNK ended the quarter with $8.8 million in cash, down from $9.5 million at the end of the first quarter, while quarterly operating cash use increased to $2.1 million as the Phase II trial was operationalized. The company continues to report losses and did not provide explicit cash-runway guidance.

MiNK Therapeutics Stock Performance

INKT stock traded down $0.36 during midday trading on Thursday, reaching $11.00. 8,592 shares of the company’s stock traded hands, compared to its average volume of 9,561. The firm has a market capitalization of $54.78 million, a PE ratio of -3.87 and a beta of 0.48. The company has a 50-day moving average price of $11.34 and a two-hundred day moving average price of $11.23. MiNK Therapeutics has a 52 week low of $8.48 and a 52 week high of $18.17.

Institutional Trading of MiNK Therapeutics

A hedge fund recently raised its stake in MiNK Therapeutics stock. Geode Capital Management LLC grew its stake in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,247 shares of the company’s stock after buying an additional 1,441 shares during the period. Geode Capital Management LLC owned 0.30% of MiNK Therapeutics worth $159,000 at the end of the most recent reporting period. 2.87% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Zacks Research upgraded MiNK Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 14th. HC Wainwright reissued a “buy” rating and issued a $35.00 price objective on shares of MiNK Therapeutics in a report on Monday, May 18th. Weiss Ratings upgraded MiNK Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, July 6th. Finally, Wall Street Zen raised shares of MiNK Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.00.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell?to?cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor?associated macrophages and boost T cell–mediated tumor clearance.